The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...